{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:28:09Z","timestamp":1788874089865,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,19]],"date-time":"2027-05-19T00:00:00Z","timestamp":1810684800000},"content-version":"am","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA267275"],"award-info":[{"award-number":["R21 CA267275"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:03:54Z","timestamp":1771434234000},"page":"559.e1-559.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6110-7164","authenticated-orcid":false,"given":"Amber","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taewoong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5499-5582","authenticated-orcid":false,"given":"Xiaobei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Bellavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-394X","authenticated-orcid":false,"given":"Kimberly","family":"Burcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-2723","authenticated-orcid":false,"given":"Daniel","family":"Schrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8342-9424","authenticated-orcid":false,"given":"Erin","family":"Eberwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2725-3812","authenticated-orcid":false,"given":"Parker","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaima","family":"Jabbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrell","family":"Coring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana Costa","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwynn","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-036X","authenticated-orcid":false,"given":"Jonathan","family":"Huggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Rowe-Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-8732","authenticated-orcid":false,"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.02.009_bib0001","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.009_bib0003","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jtct.2026.02.009_bib0004","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.02.009_bib0005","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.009_bib0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.009_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jtct.2026.02.009_bib0008","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.009_bib0009","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjh.19302","article-title":"Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: a real-world multicentre study","volume":"204","author":"Dima","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.02.009_bib0010","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.009_bib0011","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.009_bib0012","doi-asserted-by":"crossref","first-page":"122","DOI":"10.56875\/2589-0646.1047","article-title":"Understanding the etiology of pancytopenias in the CAR T-cell therapy setting: what we know and what we don\u2019t?","volume":"15","author":"Yassine","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.009_bib0013","first-page":"1254","article-title":"Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies","volume":"110","author":"Beyar-Katz","year":"2025","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.jtct.2026.02.009_bib0014","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.009_bib0015","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01119-2","article-title":"Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management","volume":"14","author":"Khurana","year":"2024","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.jtct.2026.02.009_bib0017","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0018","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7_Supplement_1","key":"10.1016\/j.jtct.2026.02.009_bib0019","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1212\/01.wnl.0001051268.39803.c2","article-title":"Progressive multiple cranial neuropathies as a manifestation of ICANS following CAR-T","volume":"103","author":"Lazzari","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.009_bib0020","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3324\/haematol.2023.283296","article-title":"Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells","volume":"109","author":"Kathari","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.009_bib0021","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/19418744231167290","article-title":"Chimeric antigen receptor-T cell mediated bilateral facial nerve palsy: a case report","volume":"13","author":"Patrick","year":"2023","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jtct.2026.02.009_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1494986","article-title":"Influence of CAR T-cell therapy associated complications","volume":"15","author":"Umair","year":"2025","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.009_bib0023","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jtct.2026.02.009_bib0024","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.009_bib0025","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.009_bib0026","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.02.009_bib0027","article-title":"Adverse events and side effects of Chimeric Antigen Receptor (CAR) T cell therapy in patients with hematologic malignancies","volume":"1","author":"Kozani","year":"2021","journal-title":"Trends Med Sci"},{"issue":"14","key":"10.1016\/j.jtct.2026.02.009_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142585","article-title":"Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T cell therapy: a comprehensive imaging-based review","volume":"16","author":"Pozzessere","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.009_bib0029","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.009_bib0030","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.009_bib0032","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.02.009_bib0033","unstructured":"CTEP Common Terminology Criteria for Adverse Events (CTCAE): protocol development. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed April 7, 2025."},{"key":"10.1016\/j.jtct.2026.02.009_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"10.1016\/j.jtct.2026.02.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2026.02.009_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell\u2014associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0037","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","article-title":"Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy","volume":"8","author":"Peres","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.009_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1021612","article-title":"Myeloid-derived suppressor cell: a crucial player in autoimmune diseases","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-022-00398-3","article-title":"Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy","volume":"11","author":"Raskov","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jtct.2026.02.009_bib0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1471-2474-15-281","article-title":"Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study","volume":"15","author":"Kurk\u00f3","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.009_bib0041","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/art.34494","article-title":"Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis","volume":"64","author":"Egelston","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.009_bib0042","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clim.2015.02.001","article-title":"Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation","volume":"157","author":"Zhang","year":"2015","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0043","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/annrheumdis-2014-205508","article-title":"Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis","volume":"75","author":"Guo","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.009_bib0044","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41423-021-00832-3","article-title":"Neutrophils in chronic inflammatory diseases","volume":"19","author":"Herrero-Cervera","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.009_bib0045","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2337\/db12-1345","article-title":"Reduction of circulating neutrophils precedes and accompanies type 1 diabetes","volume":"62","author":"Valle","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jtct.2026.02.009_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1578590","article-title":"Partial depletion of circulating neutrophil granulocytes in mice exacerbates the inflammatory response and hypothermia during LPS induced severe systemic inflammation","volume":"16","author":"Hernandez","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.009_bib0047","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor\u2014associated arthritis","volume":"27","author":"Ghosh","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.009_bib0048","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/rheumatology\/keae343","article-title":"Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study","volume":"64","author":"Bass","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.009_bib0049","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.009_bib0050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12832","article-title":"Immune check point inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis","volume":"294","author":"Cappelli","year":"2020","journal-title":"Immunol Rev"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:09:34Z","timestamp":1780312174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636726001120"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}